Thesis:
Csoka, K.: The Fluorometric Microculture Cytotoxicity Assay (FMCA) in assessment of the clinical activity of cytotoxic drugs. With special reference to ovarian carcinoma. Comprehensive Summary, Uppsala University, Faculty of Medicine, 690.
Original Papers:
von Heideman, A., Sandstrom, M., Csoka, K., et al. (2000). Evaluation of drug interactions in the established FEC regimen in primary cultures of tumor cells from patients. Ann Oncol., 10, 1301-1307. (link to text)
Dhar, S., Gullbo, J., Csoka, K., et al. (2000). Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer, 6, 803-809. (link to text)
Gati, I., Bergstrom, M., Westerberg, G., Csoka, K., et al. (1990). Effects of prostaglandin.
and leukotrine inhibitors on the growth of human glioma spheroids.Eur J Cancer, 26, (7) 802-807.Gati, I., Bergstrom, M., Csoka, K., et al. (1990). Effects of the 5-lypoxygenase inhibitors AA-863 and U-60, 275 on human glioma cell lines Prostaglandins Leukotrines & Essential Fatty Acids, 40, (2) 117-124.
Larsson, R., Fridborg, H., Csoka, K., et al. (1992). Cytotoxic actions of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. Anticancer Res., 12, 1581-1586. (Link to text)
Larsson, R., Jonsson, B., Csoka, K., et al. (1992). Selective cytotoxicity activity of cyclosporins against tumor cells from patients with chronic lymphocytic leukemia. Eur J Pharmacology, 228, 237-240. (Link to text)
Nygren, P., Fridborg, H., Csoka, K., et al. (1994). Detection of tumor-specific drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer, 56, 715-720. (Link to text)
Larsson. R., Fridborg, H., Liliemark, J., Csoka, K., et al. (1994). In vitro activity of 2-delorodeoxyadenosine (CdA) in primary cultures of human hematological and solid tumors. Eur J Cancer, 30A, 1022-1026.
Fridborg, H., Nygren, P., Csoka., K., et al. (1994). Activity of Cyclosporin-A and SDZ 833 as cytotoxic drug resistance modifiers in primary cultures of hematological and solid tumors. Br J Cancer, 70, 11-17.
Csoka, K., et al. (1994). Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the Fluorometric Microculture Cytotoxicity Assay (FMCA). Gynecol Oncol., 54, 163-170. (Link to text)
Nygren, P., Csoka, K., et al. (1995). The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Chremophor EL.Br J Cancer, 71, 478-481. (Link to text)
Csoka, K., et al., (1995). Evaluation of the cytotoxic activity of Gemcitabine in primary cultures of tumor cells from patients with hematologic and solid tumors. Semin Oncol., 22, 47-53. (Link to text)
Csoka, K., et al. (1995) Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Int J Cancer, 63, 356-360. (Link to text)
Dhar, S., Nygren, P., Csoka, K., et al. (1996). Anticancer drug characterization using a human cell line panel representing defined types of drug resistance. Br J Cancer, 74, 888-896.
Jonsson, B., Liminga, G., Csoka, K., et al. (1996. Cytotoxic activity of Calcein acetoxymethyl ester (Calcein/AM) against primary cultures of human hematological and solid tumors. Eur J Cancer, 32A, 883-887. (Link to text)
Csoka, K., et al. (1997). Differential activity of Chremophor EL and Paclitaxel in patient’s tumor cells and human carcinoma cell lines in vitro. Cancer, 79/6, 1225-1233. (Link to text)
Fridborg, H., Nygren, P., Csoka, K., et al. (1996). Cytotoxic activity of Vinorelbine in cell lines and fresh human tumor cells. J Exper Therapeutics & Oncology, 1, 286-295. (Link to text)
Jonsson, E., Fridborg, H., Csoka, K., et al. (1997). Cytotoxic activity of Topotecan in human tumor cell lines and primary cultures of human tumour cells from patients. Br J Cancer, 76, 211-219. (Link to text)
Csoka, K., et al. (1997). In vitro determination of cytotoxic drug-response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer, 72, 108-1012. (Link to text)
Nygren, P., Csoka, k., et al. (1999). Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. J Urol., 162/6, 2200-2204. (Link to text)
(Link to text)
Original papers, manuscripts:
1. Larsson, R., Csoka, K., et al. (1998). The ratio of systematic exposure at maximum tolerated dose and in vitro potency as a tool for prediction of clinical utility of anticancer agents in ovarian carcinoma. Manuscript.
Abstracts:
Csoka, K., et al. (1992). A feasibility study of the Fluorometric Microculture Cytotoxicity Assay (FMCA) for in vitro prediction of chemotherapeutic drug resistance in solid tumors. Anticancer Res A:472.
Csoka, K., et al. (1993). The Fluorometric Microculture Cytotoxicity Assay (FMCA) a feasible in vitro test of ovarian cancer chemosensitivity. Fourth Biennial Meeting of the International Gynecologic Cancer Society, Aug. 29-Sept. 2, Stockholm, Sweden, A:267.
Uddenfelt, U., Fridborg, H., Csoka, K., et al. (1993). Determination of in vitro chemosensitivity of malignant tumors in children (Bastemning in vitro av cytostatikakanslighet I maligna tumorer hos barn). NOPHOs XI arsmote.
Csoka, K., et al. (1994). P-glycoprotein (P-gp), p53 and bcl-2 expression in patient samples of ovarian carcinoma: Correlation with in vitro chemosensitivity and resistance modification. 1st International Conference on Reversal of Multidrug Resistance in Cancer, 1-3 Sept. St Gallen, Switzerland, A:137.
Csoka, K., et al. (1995). Chemosensitivity of ovarian carcinoma. Resistance patterns and initial in vitro/in vivo correlations using the Fluorometric Microculture Cytotoxicity Assay. Fifth Biennial Meeting of the International Gynecologic Cancer Society, Sept. 4-8, Philadelphia, PA, USA, A:175.
Dhar, S., Nygren, P., Csoka, K., et al. (1997). Feasibility of a non-clonogenic assay of primary tumor cells for new anticancer drug screening. 88th Annual Meeting of the American Association for Cancer Research, Apr. 12-16, San Diego, CA, USA, A:4070.
Fridborg, H., Jonsson, E., Csoka, K., et al. (1997). Capability of a non-clonogenic cytotoxicity assay (FMCA) to detect disease-specific activity of cytotoxic drugs in fresh human tumor cells. 88th Annual Meeting of the American Association for Cancer Research, Apr. 12-16, San Diego, CA, USA, A: 4069.